Cancer cells crave sugar: what science and evidence say today

Initial note: this article was previously published and is updated here according to scientific and divulgative criteria. It is for informational purposes only and does not replace personal medical advice.

IN BRIEF

• There is a solid body of observational studies linking overweight, obesity, and high insulin levels with an increased risk of certain cancers and cancer mortality.
• Cancer cells often exhibit metabolism geared towards high glucose utilization (a phenomenon known as the "Warburg effect"), but the involvement of insulin and IGF is complex and mediated by specific signaling pathways.
• Experimental evidence indicates that intracellular components (e.g., p38α kinase) participate in tumor metabolism and can be therapeutic targets under investigation.
• Combining epidemiological evidence, genetic studies (Mendelian randomization), and in vitro and in vivo experiments offers a more nuanced picture: biological plausibility + human associations, but not yet a single simple "cause."

Abstract: what does science say?

The relationship between diet, metabolism, and cancer is now described as multi-level: population observations show an association between obesity, hyperinsulinemia, and an increased risk of various cancers; genetic and experimental studies provide biological plausibility. Neoplastic cells frequently resort to metabolic pathways that favor glucose utilization not only as an energy source but also as raw material for cell synthesis. Insulin and related factors (IGF) can modulate signals that stimulate cell proliferation and survival; in parallel, intracellular pathways such as the p38α pathway influence the energy balance and survival of tumor cells. The evidence gathered is consistent with an important role of metabolism and the systemic metabolic environment in the development and progression of some cancers, however, the results vary by cancer type, metabolic context, and study design. The current picture calls for a clear distinction between association and causality and the use of multiple approaches (epidemiology, genetics, molecular biology) to interpret the data.

What epidemiology shows

Meta-analyses and large cohorts have shown that increased body weight is associated with an increased risk for several tumor sites; this relationship has been documented in hundreds of thousands of cases and remains one of the most robust epidemiological observations in oncology [1]. In parallel, prospective studies and analyses of population data indicate that hyperinsulinemia — elevated fasting plasma insulin levels — is associated with higher cancer mortality, even in non-obese individuals, suggesting that the mere presence of excess body fat does not explain all the risk related to metabolism [2].

To understand the possibility of a causal link, genetic techniques such as Mendelian randomization have been applied. Such analyses, which use genetic variants associated with insulin levels as "instruments," provide evidence that chronically elevated insulinemic levels can increase the risk of specific cancers, such as endometrial cancer, reducing the role of observational confounders and strengthening the biological hypothesis of a direct relationship between insulinemia and oncological risk for some sites [3].

Biological mechanisms: sugar, insulin, and tumor metabolism

In tumor tissues, a reorganization of metabolism is frequently observed: many neoplastic cells increase glucose uptake and metabolize it in a way that supports rapid proliferation — a phenomenon known in the literature as the Warburg effect and extensively studied in the last two decades [4]. This alteration is not just a "hunger" for sugars, but a rethinking of metabolic flows that favors the synthesis of biosynthetic precursors necessary for cell growth.

Insulin and related growth factors (IGF) activate receptors and intracellular pathways that promote proliferation, survival, and anabolic metabolism. Oncological reviews emphasize that insulin/IGF signaling is closely connected with tumor biology: overexpressed receptors, cross-talk with pathways like PI3K–AKT–mTOR, and modulation of processes like apoptosis are part of this picture [5][6].

At the experimental level, more specific elements have emerged: p38α kinase has been implicated in maintaining glycolytic metabolism and the survival of gastrointestinal and ovarian cancer cells. Preclinical studies show that its inhibition can induce a revolution in the transcriptional profile — from supporting HIF1α (favoring glycolysis) to activating FoxO and AMPK — with a consequent reduction in intracellular ATP, growth arrest, and increased autophagy or cell death in animal models [7][8]. These results explain at least in part how systemic signals (insulin/IGF) and intracellular components cooperate to support tumor growth.

Dose-response relationship, frequency, and context

The observed associations depend on intensity and exposure: chronically elevated levels of insulin or IGF can have different effects compared to transient fluctuations. Furthermore, the role of insulin varies according to the tumor site, the individual's hormonal status, and the presence of other metabolic conditions (insulin resistance, inflammation, body composition). In summary, the effect is not universal but contextual: dose and duration of metabolic exposure matter, as does the tumor microenvironment.

What it means in practice

The overall evidence points to two practical considerations, without direct clinical prescriptions. First, maintaining a favorable metabolic state (adequate body weight, metabolic control) is associated with a lower risk of some cancers in established observational literature [1]. Second, the complexity of the molecular pathways involved suggests that therapeutic approaches based on metabolic targets (e.g., modulation of insulin/IGF pathways or inhibition of elements like p38α) are plausible and already the subject of preclinical studies and initial human trials: however, safety, efficacy, and clinical applicability must be defined by well-controlled clinical trials [5][7][8].

For the general public, this translates into useful but cautious information: a diet and lifestyle that promote weight maintenance and metabolic quality are reasonable measures for general health; on the clinical front, any therapeutic change or decision regarding cancer risk or treatment must be discussed with a specialist doctor, possibly evaluating individual metabolic factors as part of the overall prevention or treatment strategy.

KEY POINTS TO REMEMBER

• The association between obesity, hyperinsulinemia, and increased risk of certain cancers is robust in population studies, but varies by tumor site and individual context [1][2].
• Tumor metabolism often favors glucose utilization to support growth; this does not imply that dietary sugar is a "sole cause" of cancer, but links systemic metabolism and the tumor microenvironment [4].
• Insulin and IGF activate pathways that promote cell proliferation and survival; experimental and clinical evidence supports their role as modulating factors of risk and progression [5][6].
• Experimental approaches targeting components like p38α show antitumor effects in preclinical models, but controlled clinical trials are needed to define benefits and risks [7][8].
• Distinguishing correlation from causality is essential: genetic studies (Mendelian randomization) have provided elements of causality for some sites (e.g., endometrium), but generalization requires caution [3].

Limitations of the evidence

It is important to clarify the methodological limitations that influence the conclusions. Observational studies can be influenced by confounders (smoking, hormone therapy, socioeconomic factors) and by the variability of biological measurements (different methods for insulin, IGF, C-peptide). The results do not authorize generalized causal claims without further evidence [1][2].

Mendelian randomization approaches reduce the risk of confounding and can support causal inferences; a notable example is MR linking genetically elevated insulin levels to the risk of endometrial cancer, a result that gives greater weight to the plausibility of a causal relationship at that site, while still requiring further confirmation [3].

Finally, experimental data on molecular targets (p38α and similar) largely come from cell and animal models; translation into effective and safe therapy for people requires clinical trials that evaluate efficacy, side effects, and suitable populations [7][8].

Editorial conclusion

Contemporary research outlines a complex but coherent picture: systemic metabolism and hormonal signals like insulin and IGF contribute to the microenvironment that can favor tumor transformation and progression in certain contexts. Epidemiological studies, genetic analyses, and molecular experiments converge in providing biological plausibility and potential therapeutic indications. However, there is no single isolable "culprit": genetic, metabolic, environmental, and behavioral factors interact. For the citizen, the prudent recommendation is to adopt behaviors favorable to metabolic health and consult their doctor for personalized decisions. For the scientific community, the challenge is to complete clinical translation with rigorous trials that test the hypotheses generated by preclinical models.

Editorial note

This article is an updated version of previously published content. The update was carried out following criteria of scientific evidence, divulgative clarity, and transparency of sources. The purpose is informative; it does not constitute a therapeutic recommendation or replace specialist medical advice.

SCIENTIFIC RESEARCH

1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–578. https://doi.org/10.1016/S0140-6736(08)60269-X
2. Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer. 2017;141(1):102–111. https://doi.org/10.1002/ijc.30729
3. Nead KT, Sharp SJ, Thompson DJ, et al. Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. J Natl Cancer Inst. 2015;107(9):djv178. https://doi.org/10.1093/jnci/djv178
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. https://doi.org/10.1126/science.1160809
5. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159–169. https://doi.org/10.1038/nrc3215
6. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology. 2011;152(7):2546–2551. https://doi.org/10.1210/en.2011-0231
7. Chiacchiera F, Matrone A, Ferrari E, et al. p38α blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1α- to FoxO-dependent transcription. Cell Death Differ. 2009;16(9):1203–1214. https://doi.org/10.1038/cdd.2009.36
8. Chiacchiera F, Simone C. Inhibition of p38α unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy. 2009;5(7):1030–1033. https://doi.org/10.4161/auto.5.7.9252

[If some bibliographic details or metadata are missing, standard placeholders have been left in square brackets. Each listed DOI has been verified and corresponds to the cited article.]